Conference
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).
Abstract
73
Background: Older adults are at greater risk of cognitive decline with various oncologic therapies. Emerging data suggest cognitive effects of various therapies for mCRPC but study populations are highly selected and published data are limited and focus mostly on self-reported cognitive function. We evaluated the effects of treatment with docetaxel chemotherapy (CHEMO), abiraterone (ABI), enzalutamide (ENZA), and radium 223 …
Authors
Alibhai SMH; Breunis H; Timilshina N; Hansen AR; Joshua AM; Warde PR; Gregg RW; Fleshner NE; Tomlinson G; Hotte SJ
Volume
38
Pagination
pp. 73-73
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2020
DOI
10.1200/jco.2020.38.6_suppl.73
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X